Intramuscular Vaccine Adjuvants Market is estimated to be valued at USD 790.8 Mn in 2025 and is expected to reach USD 1,245.1 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.
The global intramuscular vaccine adjuvants market demand is growing due to rising need for more effective vaccines and increasing prevalence of infectious diseases. Intramuscular adjuvants, including oil-based, liposome-based, polymer-based, and mineral-based types, enhance immune response, which is crucial for infectious disease and cancer vaccines.
|
Current Events |
Description and its Impact |
|
Advances in Adjuvant Nanotechnology and Formulation |
|
|
Policy and Funding Shifts in Global Health Initiatives |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of application, the infectious diseases segment is projected to hold the greatest share of the global intramuscular vaccine adjuvants market in 2025, driven by the increasing prevalence of infectious diseases worldwide. Vaccines often require adjuvants to enhance the body’s immune response, ensuring stronger and longer-lasting protection against pathogens. With the rise of diseases such as influenza, hepatitis, and emerging viral infections, there is a growing need for more effective vaccines. Adjuvants help improve immunogenicity, reduce the amount of antigen needed per dose, and can enable broader protection across populations with varying immune profiles.
For instance, in April 2025, a recent study published in ImmunoHorizons identified EmT4™, a synthetic vaccine adjuvant, as a promising candidate for enhancing tuberculosis (TB) vaccines. Developed by Dr. Rhea Coler and her team at Seattle Children’s Hospital, EmT4™ is a TLR4 agonist formulated in an oil-in-water emulsion. When combined with TB vaccine candidates ID93 or ID91, EmT4™ stimulated robust TH1-biased immune responses and significantly reduced bacterial burden in both standard and immunocompromised animal models.
In terms of adjuvants, the oil-based adjuvants segment is expected to contribute the largest share of the market in 2025, due to their proven ability to enhance immune responses effectively. They work by forming a depot at the injection site, which allows for slow and sustained release of antigens, resulting in a stronger and longer-lasting immunity. Additionally, oil-based adjuvants such as MF59 and Freund’s adjuvant have an established safety profile and are widely used in vaccines for influenza, veterinary applications, and other infectious diseases. Their compatibility with various antigens, ease of formulation, and ability to boost both humoral and cellular immunity make them preferred over newer or less-tested adjuvant types. The combination of efficacy, reliability, and regulatory familiarity drives their strong demand in the market.
For instance, in February 2025, OZ Biosciences introduced SqualVax Vegetal, an oil-in-water emulsion adjuvant derived from plant-based phytosqualene sourced from premium European olive oil. This innovation offers a sustainable alternative to traditional squalene, typically extracted from animal sources. Designed to enhance immune responses, SqualVax Vegetal is fully biodegradable and free from animal-derived components.
In terms of end user, the pediatrics segment is set to account for the highest share of the market in 2025, as children require multiple vaccinations to build immunity against various infectious diseases. Intramuscular adjuvants enhance the immune response, ensuring vaccines are more effective and provide longer-lasting protection, which is especially critical for infants and young children with developing immune systems. Additionally, pediatric vaccines often target highly contagious diseases such as influenza, measles, and whooping cough, where robust immune stimulation is essential.
For instance, in October 2023, Inimmune Corporation, a clinical-stage biotechnology firm, partnered with Boston Children’s Hospital to develop innovative small-molecule vaccine adjuvants aimed at enhancing immune responses. The collaboration focuses on a TLR7/8 agonist adjuvant to improve the efficacy of flu vaccines. This initiative is supported by a five-year, $9 million contract from the NIH/NIAID's Vaccine Adjuvant Development Program.
In terms of distribution channel, the hospitals segment is expected to hold the enormous share of the market in 2025, as these adjuvants enhance vaccine efficacy, ensuring stronger and longer-lasting immune responses for patients. They are especially critical for immunizations against infectious diseases and certain cancers, where a robust immune response is essential. Hospitals also benefit from intramuscular adjuvants’ ability to reduce the number of vaccine doses needed, improving patient compliance and vaccination coverage. Additionally, with increasing vaccination campaigns, rising awareness of preventive healthcare, and the need to protect vulnerable populations such as children, the elderly, and immunocompromised patients, hospitals are increasingly procuring vaccines containing intramuscular adjuvants to optimize treatment outcomes and overall public health impact, further proliferating the intramuscular vaccine adjuvants market revenue.
For instance, in April 2025, the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) launched the Vaccine Integrity Project to safeguard U.S. vaccine use amid rising misinformation and policy shifts. The initiative aims to ensure vaccines remain grounded in scientific evidence and free from external influence. The project will focus on developing evidence-based immunization recommendations, addressing misinformation, and fostering collaboration among healthcare providers, public health officials, and medical societies.
To learn more about this report, Download Free Sample
North America held the largest share of the intramuscular vaccine adjuvants market in 2025, and is expected to maintain its dominance during the forecast period. This can be attributed to the high prevalence of infectious diseases in the region, along with the presence of key market players. Additionally, the increasing adoption of advanced technologies for vaccine development is expected to further fuel the intramuscular vaccine adjuvants market growth in North America.
For instance, in August 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded USD 5 million to Boost Biopharma to advance its rapid antigen design technology. This funding aims to accelerate the creation of protein-based vaccines against emerging viral threats, including SARS-CoV-2 and its variants. Boost's approach utilizes stable, easily purified antigens that can be produced at scale and stored without refrigeration, enhancing global accessibility.
The Asia-Pacific region is projected to witness the fastest growth rate during the forecast period, owing to the increasing investments in vaccine development by both public and private organizations. Additionally, the rising prevalence of infectious diseases and the increasing awareness about the benefits of vaccination are expected to further drive market growth in this region. The large population base in countries like China and India also presents a significant growth opportunity for the intramuscular vaccine adjuvants market in the region.
For instance, in December 2024, Serum Institute of India (SII) and Valneva SE have entered into an exclusive license agreement to expand access to Valneva’s single-dose chikungunya vaccine across Asia. This collaboration aims to address the urgent public health need amid a significant outbreak in India. Under the agreement, Valneva will supply the vaccine's drug substance to SII, which will handle manufacturing and regulatory approvals in India and other Asian countries. The partnership includes a profit-sharing model and milestone payments, with SII committing to supply affordable doses to low- and middle-income countries and stockpiling 100,000 doses for potential clinical trials and outbreak response.
The U.S. leads in the intramuscular vaccine adjuvants market, driven by advanced healthcare infrastructure, substantial investments in vaccine research and development, and a high prevalence of vaccine-preventable diseases. The country's robust pharmaceutical industry and regulatory support further bolster the demand for effective vaccine adjuvants. According to the WHO, Vaccines have saved more than 150 million lives over the past five decades in the United States.
For instance, from April 26 to May 3, 2025, the Pan American Health Organization (PAHO) led the 23rd annual Vaccination Week in the Americas (VWA) alongside the 14th World Immunization Week (WIW). Under the theme “Your decision makes a difference. Immunization for all,” the initiative aimed to bolster vaccine equity across the region. This year's campaign aligns with PAHO’s Disease Elimination Initiative, targeting the eradication of over 30 communicable diseases by 2030, including 11 vaccine-preventable ones.
India is emerging as a key player in the vaccine adjuvants market, with a growing biotechnology sector and increasing collaborations between Indian pharmaceutical companies and international vaccine developers. The government's proactive support for domestic vaccine development and expanding vaccination programs are driving the intramuscular vaccine adjuvants market demand.
For instance, in June 2025, Bharat Biotech International Limited (BBIL), based in Hyderabad, secured in-licensing rights for GSK's Shigella vaccine candidate, altSonflex1-2-3. This collaboration aims to advance the development of a vaccine targeting Shigellosis, a severe diarrheal disease primarily affecting children under five in low- and middle-income countries. The vaccine utilizes GSK's innovative Generalized Modules for Membrane Antigens (GMMA) technology, which employs bacterial outer membrane vesicles to stimulate a robust immune response.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 790.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.7% | 2032 Value Projection: | USD 1,245.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, OZ Biosciences |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The Intramuscular Vaccine Adjuvants market value is poised to reflect a shift in strategic focus toward formulations that enhance immunogenicity while minimizing reactogenicity. Oil-based adjuvants continue to dominate clinical preference, particularly in influenza and hepatitis vaccines, due to their proven efficacy in eliciting robust humoral responses. However, emerging evidence suggests that liposome-based adjuvants are rapidly gaining traction in early-stage clinical trials, especially for recombinant protein vaccines, owing to their ability to target antigen-presenting cells effectively and modulate cellular immunity. For instance, studies indicate that liposomal formulations can increase antigen-specific T-cell proliferation by up to 60% compared with traditional mineral-based adjuvants, highlighting their potential in next-generation vaccine platforms.
Polymer-based adjuvants are increasingly being explored for sustained-release delivery, improving antigen stability and reducing dosing frequency, which can significantly enhance patient compliance in pediatric and geriatric populations. Notably, the integration of synthetic polymers in influenza and RSV vaccines has shown a measurable improvement in antibody titers, with a reported 40–50% increase in neutralizing activity compared to unadjuvanted controls in preclinical models.
From a commercial standpoint, vaccine developers are strategically prioritizing adjuvants with flexible compatibility across multiple antigens, as this reduces formulation development time and accelerates regulatory approval. The preference for modular adjuvant platforms is particularly evident in the oncology vaccine space, where immune system specificity is paramount, and safety margins are narrow. Mineral-based adjuvants, while historically widespread, are gradually being supplemented or replaced in high-value therapeutic vaccines due to localized reactogenicity concerns and limited efficacy in stimulating cell-mediated immunity.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
